Surprisingly, it has been reported that silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β−catenin signaling pathway (Liu et al., 2019), implying that RRM2 may be a new therapeutic target for MM. This evidence concerns the gene RRM2 and plasma cell myeloma.